About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals is a company based in Lexington (United States) founded in 2007 was acquired by Novo Nordisk in November 2021.. Dicerna Pharmaceuticals has raised $106.45 million across 7 funding rounds from investors including Lilly, Novo Nordisk and RA Capital. The company has 337 employees as of December 31, 2021. Dicerna Pharmaceuticals offers products and services including Wegovy and Ozempic. Dicerna Pharmaceuticals operates in a competitive market with competitors including Alnylam, Denali Therapeutics, Avidity Biosciences, Poseida Therapeutics and Castle Biosciences, among others.
- Headquarter Lexington, United States
- Employees 337 as on 31 Dec, 2021
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Dicerna Pharmaceuticals Inc
-
Annual Revenue
$164.31 M587as on Dec 31, 2020
-
Net Profit
$-112.75 M6as on Dec 31, 2020
-
EBITDA
$-113.21 M12as on Dec 31, 2020
-
Total Equity Funding
$106.45 M (USD)
in 7 rounds
-
Latest Funding Round
$100 M (USD), Post-IPO
Dec 19, 2018
-
Investors
Lilly
& 16 more
-
Employee Count
337
as on Dec 31, 2021
-
Acquired by
Novo Nordisk
(Nov 18, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Dicerna Pharmaceuticals
Dicerna Pharmaceuticals offers a comprehensive portfolio of products and services, including Wegovy and Ozempic. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medication for weight management in adults with obesity.
Drug for managing type 2 diabetes and related conditions.
Unlock access to complete
Unlock access to complete
Leadership Team
275 people
Software Development Team
233 people
Senior Team
108 people
Product Management Team
58 people
Finance and Accounting
53 people
Human Resources and Administration
53 people
Operations Team
44 people
Data Analysis and Operations Team
42 people
Unlock access to complete
Funding Insights of Dicerna Pharmaceuticals
Dicerna Pharmaceuticals has successfully raised a total of $106.45M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $100.0M
-
First Round
First Round
(15 Jul 2008)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2018 | Amount | Post-IPO - Dicerna Pharmaceuticals | Valuation |
investors |
|
| Mar, 2017 | Amount | Post-IPO - Dicerna Pharmaceuticals | Valuation |
investors |
|
| Aug, 2013 | Amount | Series C - Dicerna Pharmaceuticals | Valuation | RA Capital Management |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Dicerna Pharmaceuticals
Dicerna Pharmaceuticals has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Novo Nordisk and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science & tech focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
US life sciences companies are invested in by Skyline Ventures.
|
Founded Year | Domain | Location | |
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Dicerna Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Dicerna Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Dicerna Pharmaceuticals Comparisons
Competitors of Dicerna Pharmaceuticals
Dicerna Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Denali Therapeutics, Avidity Biosciences, Poseida Therapeutics and Castle Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Dicerna Pharmaceuticals
Frequently Asked Questions about Dicerna Pharmaceuticals
When was Dicerna Pharmaceuticals founded?
Dicerna Pharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Where is Dicerna Pharmaceuticals located?
Dicerna Pharmaceuticals is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Is Dicerna Pharmaceuticals a funded company?
Dicerna Pharmaceuticals is a funded company, having raised a total of $106.45M across 7 funding rounds to date. The company's 1st funding round was a Series C of $60M, raised on Jul 15, 2008.
How many employees does Dicerna Pharmaceuticals have?
As of Dec 31, 2021, the latest employee count at Dicerna Pharmaceuticals is 337.
What is the annual revenue of Dicerna Pharmaceuticals?
Annual revenue of Dicerna Pharmaceuticals is $164.31M as on Dec 31, 2020.
What does Dicerna Pharmaceuticals do?
Founded in 2007, Dicerna Pharmaceuticals is based in Lexington, United States, within the biotechnology sector. Therapeutics are developed through RNA interference technology for various conditions. A lead RNA product targets hepatocellular carcinoma, while other candidates address primary hyperoxaluria, genetic liver diseases, cardiovascular issues, and hepatitis B virus. The GalXC platform is applied to silence genes associated with these diseases.
Who are the top competitors of Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals's top competitors include Juno Therapeutics, Alnylam and Avidity Biosciences.
What products or services does Dicerna Pharmaceuticals offer?
Dicerna Pharmaceuticals offers Wegovy and Ozempic.
Who are Dicerna Pharmaceuticals's investors?
Dicerna Pharmaceuticals has 17 investors. Key investors include Lilly, Novo Nordisk, RA Capital, Bain Capital Private Equity, and Abingworth.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.